VERU

VERU

USD

Veru Inc. Common Stock

$2.650+0.070 (2.713%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$2.580

High

$2.650

Low

$2.580

Volume

0.18M

Company Fundamentals

Market Cap

42.5M

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.18M

Exchange

NCM

Currency

USD

52-Week Range

Low $2.42Current $2.650High $14.2

AI Analysis Report

Last updated: Nov 10, 2025
AI-GeneratedData Source: Yahoo Finance, Bloomberg, SEC

VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges

Market Snapshot

Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns


Recent Performance: Turbulent Descent

Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:

  • Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
  • Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
  • Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.

Technical Signals: Mixed Messages

  • Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
  • Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
  • MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.

Fundamentals: Value Trap or Hidden Potential?

  • Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
  • **High-Risk

Related News

GlobeNewswire

Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

View more
Veru to Present Two Abstracts at ObesityWeek 2025
GlobeNewswire

Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

View more
Veru Announces Pricing of $25 Million Public Offering

AI PredictionBeta

AI Recommendation

Bullish

Updated at: Nov 10, 2025, 02:42 PM

BearishNeutralBullish

58.4% Confidence

Risk & Trading

Risk Level3/5
Medium Risk
Suitable For
Value
Trading Guide

Entry Point

$2.52

Take Profit

$2.61

Stop Loss

$2.30

Key Factors

PDI 15.4 is above MDI 14.1 with ADX 19.0, suggesting bullish trend
Trading volume is 1.9x average (3,174), indicating increased market participation
MACD 0.0119 is below signal line 0.0162, indicating a bearish crossover

Stay Updated

Set price alerts, get AI analysis updates and real-time market news.